Investment House LLC Grows Position in Amgen Inc. (NASDAQ:AMGN)

Investment House LLC increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,531 shares of the medical research company's stock after acquiring an additional 950 shares during the period. Investment House LLC's holdings in Amgen were worth $9,261,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Blossom Wealth Management raised its stake in shares of Amgen by 3.5% during the 4th quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company's stock worth $284,000 after buying an additional 37 shares during the period. Zullo Investment Group Inc. increased its holdings in Amgen by 2.8% in the 4th quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company's stock worth $356,000 after acquiring an additional 37 shares in the last quarter. Trillium Asset Management LLC raised its position in Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company's stock worth $237,000 after acquiring an additional 37 shares during the period. Brooklyn Investment Group lifted its holdings in Amgen by 1.1% during the third quarter. Brooklyn Investment Group now owns 3,377 shares of the medical research company's stock valued at $1,088,000 after purchasing an additional 38 shares in the last quarter. Finally, Prestige Wealth Management Group LLC grew its position in shares of Amgen by 2.8% in the third quarter. Prestige Wealth Management Group LLC now owns 1,387 shares of the medical research company's stock valued at $447,000 after purchasing an additional 38 shares during the period. 76.50% of the stock is owned by institutional investors.

Remove Ads

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is currently owned by corporate insiders.

Amgen Trading Up 0.3 %

Shares of NASDAQ AMGN traded up $1.00 during mid-day trading on Friday, reaching $316.04. 9,994,350 shares of the company's stock were exchanged, compared to its average volume of 2,553,454. The company's 50-day moving average is $297.24 and its 200-day moving average is $298.80. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market capitalization of $169.78 billion, a price-to-earnings ratio of 41.86, a PEG ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 annualized dividend and a dividend yield of 3.01%. Amgen's dividend payout ratio is currently 126.09%.

Analyst Ratings Changes

Several research firms recently weighed in on AMGN. Redburn Partners reduced their price target on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Bank of America increased their target price on Amgen from $275.00 to $294.00 and gave the company an "underperform" rating in a report on Wednesday, March 5th. Truist Financial lowered their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. Piper Sandler Companies reissued an "overweight" rating and issued a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Finally, Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.